Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol

This study will look at virologically suppression of patients with HIV who receive pharmacist or case management care.

Completed

Looking for future studies?

Key information

Conditions

HIV Acquired Immunodeficiency Syndrome Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

One Community Health

Sacramento, California, 95831, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with a baseline viral load > 200 copies/ml
Patients who agree to program enrollment
Patients ≥ 18 years of age

Exclusion criteria

Pregnant women
Adults unable to consent
Prisoners

Treatment and study plan

Service of care

Other

Subjects will be receiving care from case management or clinical pharmacy.

Primary outcomes

Percentage of virological suppression

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

University of California, Davis

Other

Registry information

Official study title

Virological Suppression in HIV Positive Patients Involved in a Novel, Standardized Adherence Protocol

Important dates

Study start: 2018
Primary completion: 2018
Study completion: 2018
First posted: May 7, 2018
Registry last updated: Jul 31, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed